미국의 반려동물 감염증 진단 시장 규모, 점유율, 동향 분석 보고서 : 동물 유형별, 감염 유형별, 제품별, 기술별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Companion Animal Infectious Disease Diagnostics Market Summary

The U.S. companion animal infectious disease diagnostics market size was estimated at USD 380.6 million in 2024 and is projected to reach USD 635.3 million by 2033, growing at a CAGR of 6.02% from 2025 to 2033. The market growth is fueled by factors such as the rising incidence of infectious diseases, the growing integration of advanced technologies, increasing regulatory approvals for companion animal diagnostic devices, and expanding public-private partnerships in the country.

In the U.S. companion animal diagnostics space, innovation is rapidly accelerating by combining advanced technologies and integrative research models. Leading experts in veterinary diagnostics emphasize that artificial intelligence (AI) plays an increasingly central role in transforming everything from bloodwork and urinalysis to imaging platforms and medical record systems.

AI powered analyzers such as Zoetis's Vetscan OptiCell and Imagyst enable faster, more accurate identification of blood cell abnormalities and pathological changes during routine clinic workflows. These systems reduce variability and lighten the workload on veterinary staff while delivering real time support for diagnostic decisions. In imaging, machine learning models trained on millions of x ray and ultrasound images can detect subtle patterns in canine and feline scans, offering near-human-expert diagnostic performance and much quicker turnaround times. AI integration into record keeping, scheduling, SOAP note automation, and trend analysis tools is also streamlining practice management, improving consistency, and freeing veterinarians to focus on patient care and client communication.

At the same time, One Health research initiatives, such as the May 2025 collaboration between Texas A&M and the University of Georgia on Chagas disease in dogs, are reshaping diagnostic priorities by tackling zoonotic infections within a combined animal/human health frame. Backed by over USD 4 million in recent funding, these researchers are developing sensitive diagnostic panels (DNA based and serologic biomarkers), staging protocols, and modified therapeutic regimens to manage Trypanosoma cruzi infection in canine cohorts at high risk in southern U.S. settings. By monitoring privately owned pets and working dogs, researchers are gathering clinical and ecological data to capture disease progression, cardiac impact, and exposure routes, feeding directly into improved diagnostics and early intervention strategies. The One Health approach ensures that advances in canine diagnostics and treatment protocols can directly inform human health applications in endemic regions.

Other converging trends fueling growth in companion diagnostics include the increasing complexity of pet care (pet aging, comorbidities), workforce constraints in the veterinary sector, and rising demand for rapid and trustworthy diagnostic results. With connectivity and telemedicine tools, clinics can leverage cloud based AI platforms, remote interpretation services, and decision support systems to make smarter clinical choices more efficiently.

To conclude, these developments, like AI enabled diagnostic technologies delivering heightened speed and accuracy, combined with integrative One Health research collaborations, are propelling the companion animal diagnostics industry forward. They enable veterinarians to detect disease earlier, personalize treatment protocols, optimize clinic operations, and align animal health efforts with broader public health goals. Innovations such as hematology analyzers, imaging AI, and disease diagnostic pipelines exemplify how science, clinical practice, and cross disciplinary collaboration drive a new era of precision veterinary medicine in the U.S.

U.S. Companion Animal Infectious Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal infectious disease diagnostics market report based on animal type, product, technology, Infection type, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables, Reagents & Kits
• Equipment & Instruments
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunodiagnostics
  • Lateral Flow Assays
  • ELISA Test
  • Others
• Molecular Diagnostic
  • Polymerase Chain Reaction (PCR) Tests
  • Microarrays
  • Others
• Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Canine
• Feline
• Equine
• Others
• Infection Type Outlook (Revenue, USD Million, 2021 - 2033)
• Bacterial
• Viral
• Parasitic
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals and Clinics
• Veterinary Reference Laboratories
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Country Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Infectious Disease Diagnostics Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Incidence Of Infectious Diseases
    • 3.2.1.2. Growing Integration Of Advanced Technologies
    • 3.2.1.3. Increasing Regulatory Approvals For Companion Animal Diagnostic Devices
    • 3.2.1.4. Expanding Public-Private Partnerships In The Country
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardized regulations
    • 3.2.2.2. Lack of awareness in developing economies
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Companion Animal Infectious Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Disease Prevalence Analysis
  • 3.3.6. Estimated Animal Population by key countries, key species, 2024

Chapter 4. U.S. Companion Animal Infectious Disease Diagnostics Market: Animal Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Companion Animal Infectious Disease Diagnostics Market: Animal Type Movement Analysis
• 4.3. U.S. Companion Animal Infectious Disease Diagnostics Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
• 4.4. Canine
  • 4.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Feline
  • 4.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Equine
  • 4.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Infectious Disease Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Companion Animal Infectious Disease Diagnostics Market: Technology Movement Analysis
• 5.3. U.S. Companion Animal Infectious Disease Diagnostics Market Size & Trend Analysis, by technology, 2021 to 2033 (USD Million)
• 5.4. Immunodiagnostics
  • 5.4.1. Immunodiagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Lateral Flow Assays
    • 5.4.2.1. Lateral Flow Assays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. ELISA Test
    • 5.4.3.1. ELISA Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Molecular Diagnostic
  • 5.5.1. Molecular Diagnostic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Polymerase Chain Reaction (PCR) Tests
    • 5.5.2.1. Polymerase Chain Reaction (PCR) Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Microarrays
    • 5.5.3.1. Microarrays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Infectious Disease Diagnostics Market: By Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Companion Animal Infectious Disease Diagnostics Market: By Product Movement Analysis
• 6.3. U.S. Companion Animal Infectious Disease Diagnostics Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 6.3.1. Consumables, Reagents & Kits
    • 6.3.1.1. Consumables, Reagents & Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Equipment & Instruments
    • 6.3.2.1. Equipment & Instruments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Infectious Disease Diagnostics Market: By Infection Type, Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Companion Animal Infectious Disease Diagnostics Market: By Infection Type Movement Analysis
• 7.3. U.S. Companion Animal Infectious Disease Diagnostics Market Size & Trend Analysis, by Infection type, 2021 to 2033 (USD Million)
  • 7.3.1. Bacterial
    • 7.3.1.1. Bacterial Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Viral
    • 7.3.2.1. Viral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Parasitic
    • 7.3.3.1. Parasitic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Others
    • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Companion Animal Infectious Disease Diagnostics Market: By End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Companion Animal Infectious Disease Diagnostics Market: By End Use Movement Analysis
• 8.3. U.S. Companion Animal Infectious Disease Diagnostics Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
  • 8.3.1. Veterinary Hospitals and Clinics
    • 8.3.1.1. Veterinary Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Veterinary Reference Laboratories
    • 8.3.2.1. Veterinary Reference Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Others
    • 8.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heat Map Analysis
• 9.3. Company Profiles
  • 9.3.1. IDEXX Laboratories Inc.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Zoetis Services LLC.
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Antech Diagnostics, Inc.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Thermo Fisher Scientific, Inc
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Virbac
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. bioMerieux SA
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Neogen Corporation
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. IDVet
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Agrolabo S.p.A.
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Bio-Rad Laboratories, Inc
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Product launch
  • 9.4.4. Others
• 9.5. List of other key players